Are cancer biomarkers all they're cracked up to be? Not always, writes Monica Desai in the Guardian's science blog. Of the thousands of biomarkers researchers are aware of, only a small percentage of them is being used in the clinic to find treatments for disease. There have been successes like HER-2 in breast cancer which led to the formulation of Herceptin, Desai says, but not every biomarker turns out to be as useful.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.